Trials / Unknown
UnknownNCT04277221
ADCTA for Adjuvant Immunotherapy in Standard Treatment of Recurrent Glioblastoma Multiforme (GBM)
Autologous Dendritic Cell / Tumor Antigen (ADCTA-SSI-G1) for Adjuvant Immunotherapy in Standard Treatment of Recurrent Glioblastoma Multiforme (GBM): A Multi-center, Open-label, Randomized Phase III Clinical Trial
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 118 (estimated)
- Sponsor
- Safe Save Medical Cell Sciences & Technology Co.,Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To confirm the result of previous Phase I/II and phase II clinical trials, this trial is to test the efficacy and safety of ADCTA immunotherapy plus the standard therapy in comparison with standard therapy alone in patients with recurrent GBM.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Autologous Dendritic Cell/Tumor Antigen, ADCTA | ADCTA is an individualized cell immunotherapy co-culturing autologous dendritic cells derived from peripheral blood mononuclear cells (PBMNCs) with autologous tumor cell as antigen in order to evoke specific immune response. |
Timeline
- Start date
- 2019-09-19
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
- First posted
- 2020-02-20
- Last updated
- 2020-03-17
Locations
7 sites across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT04277221. Inclusion in this directory is not an endorsement.